Press Release

Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced the results of a clinical study with an experimental vaccine against Shigella, intestinal bacteria that…

Press Release

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns, as Chief Scientific Officer (CSO). Virgil joins Intravacc with over 25 years of scientific, clinical…

Press Release

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our primary goal to restyle Intravacc was to demonstrate our aspiration to become a meaningful organization…

Press Release

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of…

Press Release

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the world’s first prophylactic vaccine against gonorrhea, NGoXIM. For this…

Press Release

Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial Bilthoven, The Netherlands, 18 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The…

Press Release

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine BILTHOVEN, Netherlands and BASEL, Switzerland, 29 July, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, and Celonic Group, a premium biopharmaceutical contract development and manufacturing organization (CDMO), specialized in development and production of Advanced Therapy Medicinal…

Press Release

Intravacc and Leiden University developed an animal replacement method for vaccines Bilthoven, The Netherlands, 23 July 2020 – Dutch, Bilthoven based, Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication of a study in Scientific Reports on alternatives to the use of laboratory animals in vaccine…

Press Release

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio Bilthoven, The Netherlands, 1 July 2020 – Bilthoven, The Netherlands based Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines, today announced the signing of a strategic partnership agreement with Dutch based…

Press Release

Intranasal immunization with Intravacc’s experimental whooping cough vaccine confers broad protection Bilthoven, The Netherlands, 22 June 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced promising results of a preclinical study with its experimental whooping cough vaccine in…